• The test methods and specifications you use to analyze each batch of drug product prior to release, including both chemical and microbial quality attributes. Include a summary of all test results obtained from full testing of all batches of OTC drug products intended for the U.S. market still within expiry.
• Timelines for testing all in-date drug products intended for the U.S., for identity and strength of active ingredients and all other appropriate quality attributes, including total count and objectionable microorganisms. If you find that you released any batch for which release test results were found to be out-of-specification, indicate the corrective actions you will take, such as customer notifications and product recalls.
• Batch release specifications for all incoming components. Describe the tests you will conduct for each batch of incoming components.
• A summary of test results obtained from full testing of each of your incoming components to validate suppliers’ certificates of analysis. Include your procedures to ensure that you test for the identity of each incoming lot of components.
• Your procedures to ensure that you test all lots of (b)(4). Provide a current risk assessment of all OTC drug products that contain (b)(4) intended for the U.S. market still within expiry. Provide the results of the testing of retain samples of these lots for (b)(4) and (b)(4).
• A current risk assessment of the OTC drug products intended for the U.S. market still within expiry that are not supported by adequate stability testing.
• Timelines for process performance qualification for each of your drug products. For any drugs distributed to the U.S. before validation activities are completed, provide an interim plan to ensure the quality of drug products that you continue to manufacture and distribute. Provide a detailed summary of your approach for routinely monitoring intra-batch and inter-batch variation.